Hims & Hers Health Inc (NYSE:HIMS) shares traded 2.07% higher at $8.89 on Wall Street last session.
In accordance with the data, 9 analysts cover Hims & Hers Health Inc (NYSE:HIMS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $7.00, we find $11.00. Given the previous closing price of $8.71, this indicates a potential upside of 26.29 percent. HIMS stock price is now 33.92% away from the 50-day moving average and 5.32% away from the 200-day moving average. The market capitalization of the company currently stands at $1.88B.
It has been rated a hold by 4 analysts and a buy by 5. Brokers who have rated the stock have averaged $10.39 as their price target over the next twelve months.
With the price target of $11, TD Cowen recently initiated with Outperform rating for Hims & Hers Health Inc (NYSE: HIMS).
In other news, Okupe Oluyemi, Chief Financial Officer sold 6,698 shares of the company’s stock on Nov 21. The stock was sold for $51,010 at an average price of $7.62. Upon completion of the transaction, the Chief Financial Officer now directly owns 144,284 shares in the company, valued at $1.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 08, Chief Operating Officer Baird Melissa sold 9,133 shares of the business’s stock. A total of $64,735 was realized by selling the stock at an average price of $7.09. This leaves the insider owning 403,849 shares of the company worth $3.59 million. Insiders disposed of 12,853,603 shares of company stock worth roughly $114.27 million over the past 1 year. A total of 35.94% of the company’s stock is owned by insiders.
Hims & Hers Health Inc (NYSE: HIMS) opened at $8.82 on Thursday. During the past 12 months, Hims & Hers Health Inc has had a low of $5.65 and a high of $12.34. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 3.03, and a quick ratio of 2.76. The fifty day moving average price for HIMS is $6.64 and a two-hundred day moving average price translates $8.44 for the stock.
The latest earnings results from Hims & Hers Health Inc (NYSE: HIMS) was released for Sep, 2023. According to the Household & Personal Products Company, earnings per share came in at -$0.04, missing analysts’ expectations of -$0.03 by -0.01. This compares to -$0.09 EPS in the same period last year. The net profit margin was -4.50% and return on equity was -11.16% for HIMS. The company reported revenue of $226.7 million for the quarter, compared to $144.84 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 56.52 percent. For the current quarter, analysts expect HIMS to generate $245.8M in revenue.
Hims & Hers Health Inc(HIMS) Company Profile
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company’s curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
